Automatic Estimation of Ulcerative Colitis Severity from Endoscopy Videos using Ordinal Multi-Instance Learning
Authors:
Evan Schwab,
Gabriela Oana Cula,
Kristopher Standish,
Stephen S. F. Yip,
Aleksandar Stojmirovic,
Louis Ghanem,
Christel Chehoud
Abstract:
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation of the large intestine. The severity of UC is often represented by the Mayo Endoscopic Subscore (MES) which quantifies mucosal disease activity from endoscopy videos. In clinical trials, an endoscopy video is assigned an MES based upon the most severe disease activity observed in the video. For…
▽ More
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation of the large intestine. The severity of UC is often represented by the Mayo Endoscopic Subscore (MES) which quantifies mucosal disease activity from endoscopy videos. In clinical trials, an endoscopy video is assigned an MES based upon the most severe disease activity observed in the video. For this reason, severe inflammation spread throughout the colon will receive the same MES as an otherwise healthy colon with severe inflammation restricted to a small, localized segment. Therefore, the extent of disease activity throughout the large intestine, and overall response to treatment, may not be completely captured by the MES. In this work, we aim to automatically estimate UC severity for each frame in an endoscopy video to provide a higher resolution assessment of disease activity throughout the colon. Because annotating severity at the frame-level is expensive, labor-intensive, and highly subjective, we propose a novel weakly supervised, ordinal classification method to estimate frame severity from video MES labels alone. Using clinical trial data, we first achieved 0.92 and 0.90 AUC for predicting mucosal healing and remission of UC, respectively. Then, for severity estimation, we demonstrate that our models achieve substantial Cohen's Kappa agreement with ground truth MES labels, comparable to the inter-rater agreement of expert clinicians. These findings indicate that our framework could serve as a foundation for novel clinical endpoints, based on a more localized scoring system, to better evaluate UC drug efficacy in clinical trials.
△ Less
Submitted 29 September, 2021;
originally announced September 2021.
